The global market for Biopharmaceutical CDMO was valued at US$ 28160 million in the year 2024 and is projected to reach a revised size of US$ 66050 million by 2031, growing at a CAGR of 13.1% during the forecast period.

Biopharmaceutical CDMO Market

Biopharmaceutical Contract Development and Manufacturing Organizations (CDMOs) are companies that provide comprehensive services for the development and manufacturing of biopharmaceutical products. These organizations play a crucial role in the biopharmaceutical industry by offering a range of services to biotech and pharmaceutical companies, allowing them to outsource various stages of the drug development and manufacturing process.

The core global biopharmaceutical CDMO manufacturers include Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim and WuXi AppTech. The top three manufacturers account for approximately 37% of the global share. North America is the world's largest market, accounting for nearly 32% of the market share.

In terms of product type, antibodies occupy a dominant position, accounting for 36% of the market share. At the same time, in terms of application, large companies are the largest application field, accounting for 58%.

This report aims to provide a comprehensive presentation of the global market for Biopharmaceutical CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biopharmaceutical CDMO.

The Biopharmaceutical CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Biopharmaceutical CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Biopharmaceutical CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Biopharmaceutical CDMO Market Report

Report Metric	Details
Report Name	Biopharmaceutical CDMO Market
Accounted market size in year	US$ 28160 million
Forecasted market size in 2031	US$ 66050 million
CAGR	13.1%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Cell and Gene Therapies Antibodies Vaccines Other
Segment by Application	SMBs Large Companies
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, WuXi AppTech, Recipharm, Thermo Fisher Scientific, AGC Biologics, Rentschler Biopharma, KBI Biopharma, Siegfried, Aenova Group, GenScript, ProBioGen, Northway Biotech, 3P Biopharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biopharmaceutical CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Biopharmaceutical CDMO Market growing?

Ans: The Biopharmaceutical CDMO Market witnessing a CAGR of 13.1% during the forecast period 2025-2031.

What is the Biopharmaceutical CDMO Market size in 2031?

Ans: The Biopharmaceutical CDMO Market size in 2031 will be US$ 66050 million.

What is the market share of major companies in Biopharmaceutical CDMO Market?

Ans: The top three manufacturers account for approximately 37% of the global share.

What is the Biopharmaceutical CDMO Market share by region?

Ans: North America is the world's largest market, accounting for nearly 32% of the market share.

What is the Biopharmaceutical CDMO Market share by type?

Ans: In terms of product type, antibodies occupy a dominant position, accounting for 36% of the market share.

Who are the main players in the Biopharmaceutical CDMO Market report?

Ans: The main players in the Biopharmaceutical CDMO Market are Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, WuXi AppTech, Recipharm, Thermo Fisher Scientific, AGC Biologics, Rentschler Biopharma, KBI Biopharma, Siegfried, Aenova Group, GenScript, ProBioGen, Northway Biotech, 3P Biopharmaceuticals

What are the Application segmentation covered in the Biopharmaceutical CDMO Market report?

Ans: The Applications covered in the Biopharmaceutical CDMO Market report are SMBs, Large Companies

What are the Type segmentation covered in the Biopharmaceutical CDMO Market report?

Ans: The Types covered in the Biopharmaceutical CDMO Market report are Cell and Gene Therapies, Antibodies, Vaccines, Other

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Biopharmaceutical CDMO Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Cell and Gene Therapies

1.2.3 Antibodies

1.2.4 Vaccines

1.2.5 Other

1.3 Market by Application

1.3.1 Global Biopharmaceutical CDMO Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 SMBs

1.3.3 Large Companies

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Biopharmaceutical CDMO Market Perspective (2020-2031)

2.2 Global Biopharmaceutical CDMO Growth Trends by Region

2.2.1 Global Biopharmaceutical CDMO Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Biopharmaceutical CDMO Historic Market Size by Region (2020-2025)

2.2.3 Biopharmaceutical CDMO Forecasted Market Size by Region (2026-2031)

2.3 Biopharmaceutical CDMO Market Dynamics

2.3.1 Biopharmaceutical CDMO Industry Trends

2.3.2 Biopharmaceutical CDMO Market Drivers

2.3.3 Biopharmaceutical CDMO Market Challenges

2.3.4 Biopharmaceutical CDMO Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Biopharmaceutical CDMO Players by Revenue

3.1.1 Global Top Biopharmaceutical CDMO Players by Revenue (2020-2025)

3.1.2 Global Biopharmaceutical CDMO Revenue Market Share by Players (2020-2025)

3.2 Global Biopharmaceutical CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Biopharmaceutical CDMO Revenue

3.4 Global Biopharmaceutical CDMO Market Concentration Ratio

3.4.1 Global Biopharmaceutical CDMO Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Biopharmaceutical CDMO Revenue in 2024

3.5 Global Key Players of Biopharmaceutical CDMO Head office and Area Served

3.6 Global Key Players of Biopharmaceutical CDMO, Product and Application

3.7 Global Key Players of Biopharmaceutical CDMO, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Biopharmaceutical CDMO Breakdown Data by Type

4.1 Global Biopharmaceutical CDMO Historic Market Size by Type (2020-2025)

4.2 Global Biopharmaceutical CDMO Forecasted Market Size by Type (2026-2031)

5 Biopharmaceutical CDMO Breakdown Data by Application

5.1 Global Biopharmaceutical CDMO Historic Market Size by Application (2020-2025)

5.2 Global Biopharmaceutical CDMO Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Biopharmaceutical CDMO Market Size (2020-2031)

6.2 North America Biopharmaceutical CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Biopharmaceutical CDMO Market Size by Country (2020-2025)

6.4 North America Biopharmaceutical CDMO Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Biopharmaceutical CDMO Market Size (2020-2031)

7.2 Europe Biopharmaceutical CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Biopharmaceutical CDMO Market Size by Country (2020-2025)

7.4 Europe Biopharmaceutical CDMO Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Biopharmaceutical CDMO Market Size (2020-2031)

8.2 Asia-Pacific Biopharmaceutical CDMO Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Biopharmaceutical CDMO Market Size by Region (2020-2025)

8.4 Asia-Pacific Biopharmaceutical CDMO Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Biopharmaceutical CDMO Market Size (2020-2031)

9.2 Latin America Biopharmaceutical CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Biopharmaceutical CDMO Market Size by Country (2020-2025)

9.4 Latin America Biopharmaceutical CDMO Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Biopharmaceutical CDMO Market Size (2020-2031)

10.2 Middle East & Africa Biopharmaceutical CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Biopharmaceutical CDMO Market Size by Country (2020-2025)

10.4 Middle East & Africa Biopharmaceutical CDMO Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Lonza

11.1.1 Lonza Company Details

11.1.2 Lonza Business Overview

11.1.3 Lonza Biopharmaceutical CDMO Introduction

11.1.4 Lonza Revenue in Biopharmaceutical CDMO Business (2020-2025)

11.1.5 Lonza Recent Development

11.2 Catalent

11.2.1 Catalent Company Details

11.2.2 Catalent Business Overview

11.2.3 Catalent Biopharmaceutical CDMO Introduction

11.2.4 Catalent Revenue in Biopharmaceutical CDMO Business (2020-2025)

11.2.5 Catalent Recent Development

11.3 Samsung Biologics

11.3.1 Samsung Biologics Company Details

11.3.2 Samsung Biologics Business Overview

11.3.3 Samsung Biologics Biopharmaceutical CDMO Introduction

11.3.4 Samsung Biologics Revenue in Biopharmaceutical CDMO Business (2020-2025)

11.3.5 Samsung Biologics Recent Development

11.4 FUJIFILM Diosynth Biotechnologies

11.4.1 FUJIFILM Diosynth Biotechnologies Company Details

11.4.2 FUJIFILM Diosynth Biotechnologies Business Overview

11.4.3 FUJIFILM Diosynth Biotechnologies Biopharmaceutical CDMO Introduction

11.4.4 FUJIFILM Diosynth Biotechnologies Revenue in Biopharmaceutical CDMO Business (2020-2025)

11.4.5 FUJIFILM Diosynth Biotechnologies Recent Development

11.5 Boehringer Ingelheim

11.5.1 Boehringer Ingelheim Company Details

11.5.2 Boehringer Ingelheim Business Overview

11.5.3 Boehringer Ingelheim Biopharmaceutical CDMO Introduction

11.5.4 Boehringer Ingelheim Revenue in Biopharmaceutical CDMO Business (2020-2025)

11.5.5 Boehringer Ingelheim Recent Development

11.6 WuXi AppTech

11.6.1 WuXi AppTech Company Details

11.6.2 WuXi AppTech Business Overview

11.6.3 WuXi AppTech Biopharmaceutical CDMO Introduction

11.6.4 WuXi AppTech Revenue in Biopharmaceutical CDMO Business (2020-2025)

11.6.5 WuXi AppTech Recent Development

11.7 Recipharm

11.7.1 Recipharm Company Details

11.7.2 Recipharm Business Overview

11.7.3 Recipharm Biopharmaceutical CDMO Introduction

11.7.4 Recipharm Revenue in Biopharmaceutical CDMO Business (2020-2025)

11.7.5 Recipharm Recent Development

11.8 Thermo Fisher Scientific

11.8.1 Thermo Fisher Scientific Company Details

11.8.2 Thermo Fisher Scientific Business Overview

11.8.3 Thermo Fisher Scientific Biopharmaceutical CDMO Introduction

11.8.4 Thermo Fisher Scientific Revenue in Biopharmaceutical CDMO Business (2020-2025)

11.8.5 Thermo Fisher Scientific Recent Development

11.9 AGC Biologics

11.9.1 AGC Biologics Company Details

11.9.2 AGC Biologics Business Overview

11.9.3 AGC Biologics Biopharmaceutical CDMO Introduction

11.9.4 AGC Biologics Revenue in Biopharmaceutical CDMO Business (2020-2025)

11.9.5 AGC Biologics Recent Development

11.10 Rentschler Biopharma

11.10.1 Rentschler Biopharma Company Details

11.10.2 Rentschler Biopharma Business Overview

11.10.3 Rentschler Biopharma Biopharmaceutical CDMO Introduction

11.10.4 Rentschler Biopharma Revenue in Biopharmaceutical CDMO Business (2020-2025)

11.10.5 Rentschler Biopharma Recent Development

11.11 KBI Biopharma

11.11.1 KBI Biopharma Company Details

11.11.2 KBI Biopharma Business Overview

11.11.3 KBI Biopharma Biopharmaceutical CDMO Introduction

11.11.4 KBI Biopharma Revenue in Biopharmaceutical CDMO Business (2020-2025)

11.11.5 KBI Biopharma Recent Development

11.12 Siegfried

11.12.1 Siegfried Company Details

11.12.2 Siegfried Business Overview

11.12.3 Siegfried Biopharmaceutical CDMO Introduction

11.12.4 Siegfried Revenue in Biopharmaceutical CDMO Business (2020-2025)

11.12.5 Siegfried Recent Development

11.13 Aenova Group

11.13.1 Aenova Group Company Details

11.13.2 Aenova Group Business Overview

11.13.3 Aenova Group Biopharmaceutical CDMO Introduction

11.13.4 Aenova Group Revenue in Biopharmaceutical CDMO Business (2020-2025)

11.13.5 Aenova Group Recent Development

11.14 GenScript

11.14.1 GenScript Company Details

11.14.2 GenScript Business Overview

11.14.3 GenScript Biopharmaceutical CDMO Introduction

11.14.4 GenScript Revenue in Biopharmaceutical CDMO Business (2020-2025)

11.14.5 GenScript Recent Development

11.15 ProBioGen

11.15.1 ProBioGen Company Details

11.15.2 ProBioGen Business Overview

11.15.3 ProBioGen Biopharmaceutical CDMO Introduction

11.15.4 ProBioGen Revenue in Biopharmaceutical CDMO Business (2020-2025)

11.15.5 ProBioGen Recent Development

11.16 Northway Biotech

11.16.1 Northway Biotech Company Details

11.16.2 Northway Biotech Business Overview

11.16.3 Northway Biotech Biopharmaceutical CDMO Introduction

11.16.4 Northway Biotech Revenue in Biopharmaceutical CDMO Business (2020-2025)

11.16.5 Northway Biotech Recent Development

11.17 3P Biopharmaceuticals

11.17.1 3P Biopharmaceuticals Company Details

11.17.2 3P Biopharmaceuticals Business Overview

11.17.3 3P Biopharmaceuticals Biopharmaceutical CDMO Introduction

11.17.4 3P Biopharmaceuticals Revenue in Biopharmaceutical CDMO Business (2020-2025)

11.17.5 3P Biopharmaceuticals Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

3P Biopharmaceuticals

FUJIFILM Diosynth Biotechnologies

WuXi AppTech

Thermo Fisher Scientific

AGC Biologics

List of Tables

Table 1. Global Biopharmaceutical CDMO Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Cell and Gene Therapies

Table 3. Key Players of Antibodies

Table 4. Key Players of Vaccines

Table 5. Key Players of Other

Table 6. Global Biopharmaceutical CDMO Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Biopharmaceutical CDMO Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Biopharmaceutical CDMO Market Size by Region (2020-2025) & (US$ Million)

Table 9. Global Biopharmaceutical CDMO Market Share by Region (2020-2025)

Table 10. Global Biopharmaceutical CDMO Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 11. Global Biopharmaceutical CDMO Market Share by Region (2026-2031)

Table 12. Biopharmaceutical CDMO Market Trends

Table 13. Biopharmaceutical CDMO Market Drivers

Table 14. Biopharmaceutical CDMO Market Challenges

Table 15. Biopharmaceutical CDMO Market Restraints

Table 16. Global Biopharmaceutical CDMO Revenue by Players (2020-2025) & (US$ Million)

Table 17. Global Biopharmaceutical CDMO Market Share by Players (2020-2025)

Table 18. Global Top Biopharmaceutical CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biopharmaceutical CDMO as of 2024)

Table 19. Ranking of Global Top Biopharmaceutical CDMO Companies by Revenue (US$ Million) in 2024

Table 20. Global 5 Largest Players Market Share by Biopharmaceutical CDMO Revenue (CR5 and HHI) & (2020-2025)

Table 21. Global Key Players of Biopharmaceutical CDMO, Headquarters and Area Served

Table 22. Global Key Players of Biopharmaceutical CDMO, Product and Application

Table 23. Global Key Players of Biopharmaceutical CDMO, Date of Enter into This Industry

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Biopharmaceutical CDMO Market Size by Type (2020-2025) & (US$ Million)

Table 26. Global Biopharmaceutical CDMO Revenue Market Share by Type (2020-2025)

Table 27. Global Biopharmaceutical CDMO Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 28. Global Biopharmaceutical CDMO Revenue Market Share by Type (2026-2031)

Table 29. Global Biopharmaceutical CDMO Market Size by Application (2020-2025) & (US$ Million)

Table 30. Global Biopharmaceutical CDMO Revenue Market Share by Application (2020-2025)

Table 31. Global Biopharmaceutical CDMO Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 32. Global Biopharmaceutical CDMO Revenue Market Share by Application (2026-2031)

Table 33. North America Biopharmaceutical CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 34. North America Biopharmaceutical CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 35. North America Biopharmaceutical CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 36. Europe Biopharmaceutical CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. Europe Biopharmaceutical CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 38. Europe Biopharmaceutical CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 39. Asia-Pacific Biopharmaceutical CDMO Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 40. Asia-Pacific Biopharmaceutical CDMO Market Size by Region (2020-2025) & (US$ Million)

Table 41. Asia-Pacific Biopharmaceutical CDMO Market Size by Region (2026-2031) & (US$ Million)

Table 42. Latin America Biopharmaceutical CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 43. Latin America Biopharmaceutical CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 44. Latin America Biopharmaceutical CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 45. Middle East & Africa Biopharmaceutical CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Middle East & Africa Biopharmaceutical CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 47. Middle East & Africa Biopharmaceutical CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 48. Lonza Company Details

Table 49. Lonza Business Overview

Table 50. Lonza Biopharmaceutical CDMO Product

Table 51. Lonza Revenue in Biopharmaceutical CDMO Business (2020-2025) & (US$ Million)

Table 52. Lonza Recent Development

Table 53. Catalent Company Details

Table 54. Catalent Business Overview

Table 55. Catalent Biopharmaceutical CDMO Product

Table 56. Catalent Revenue in Biopharmaceutical CDMO Business (2020-2025) & (US$ Million)

Table 57. Catalent Recent Development

Table 58. Samsung Biologics Company Details

Table 59. Samsung Biologics Business Overview

Table 60. Samsung Biologics Biopharmaceutical CDMO Product

Table 61. Samsung Biologics Revenue in Biopharmaceutical CDMO Business (2020-2025) & (US$ Million)

Table 62. Samsung Biologics Recent Development

Table 63. FUJIFILM Diosynth Biotechnologies Company Details

Table 64. FUJIFILM Diosynth Biotechnologies Business Overview

Table 65. FUJIFILM Diosynth Biotechnologies Biopharmaceutical CDMO Product

Table 66. FUJIFILM Diosynth Biotechnologies Revenue in Biopharmaceutical CDMO Business (2020-2025) & (US$ Million)

Table 67. FUJIFILM Diosynth Biotechnologies Recent Development

Table 68. Boehringer Ingelheim Company Details

Table 69. Boehringer Ingelheim Business Overview

Table 70. Boehringer Ingelheim Biopharmaceutical CDMO Product

Table 71. Boehringer Ingelheim Revenue in Biopharmaceutical CDMO Business (2020-2025) & (US$ Million)

Table 72. Boehringer Ingelheim Recent Development

Table 73. WuXi AppTech Company Details

Table 74. WuXi AppTech Business Overview

Table 75. WuXi AppTech Biopharmaceutical CDMO Product

Table 76. WuXi AppTech Revenue in Biopharmaceutical CDMO Business (2020-2025) & (US$ Million)

Table 77. WuXi AppTech Recent Development

Table 78. Recipharm Company Details

Table 79. Recipharm Business Overview

Table 80. Recipharm Biopharmaceutical CDMO Product

Table 81. Recipharm Revenue in Biopharmaceutical CDMO Business (2020-2025) & (US$ Million)

Table 82. Recipharm Recent Development

Table 83. Thermo Fisher Scientific Company Details

Table 84. Thermo Fisher Scientific Business Overview

Table 85. Thermo Fisher Scientific Biopharmaceutical CDMO Product

Table 86. Thermo Fisher Scientific Revenue in Biopharmaceutical CDMO Business (2020-2025) & (US$ Million)

Table 87. Thermo Fisher Scientific Recent Development

Table 88. AGC Biologics Company Details

Table 89. AGC Biologics Business Overview

Table 90. AGC Biologics Biopharmaceutical CDMO Product

Table 91. AGC Biologics Revenue in Biopharmaceutical CDMO Business (2020-2025) & (US$ Million)

Table 92. AGC Biologics Recent Development

Table 93. Rentschler Biopharma Company Details

Table 94. Rentschler Biopharma Business Overview

Table 95. Rentschler Biopharma Biopharmaceutical CDMO Product

Table 96. Rentschler Biopharma Revenue in Biopharmaceutical CDMO Business (2020-2025) & (US$ Million)

Table 97. Rentschler Biopharma Recent Development

Table 98. KBI Biopharma Company Details

Table 99. KBI Biopharma Business Overview

Table 100. KBI Biopharma Biopharmaceutical CDMO Product

Table 101. KBI Biopharma Revenue in Biopharmaceutical CDMO Business (2020-2025) & (US$ Million)

Table 102. KBI Biopharma Recent Development

Table 103. Siegfried Company Details

Table 104. Siegfried Business Overview

Table 105. Siegfried Biopharmaceutical CDMO Product

Table 106. Siegfried Revenue in Biopharmaceutical CDMO Business (2020-2025) & (US$ Million)

Table 107. Siegfried Recent Development

Table 108. Aenova Group Company Details

Table 109. Aenova Group Business Overview

Table 110. Aenova Group Biopharmaceutical CDMO Product

Table 111. Aenova Group Revenue in Biopharmaceutical CDMO Business (2020-2025) & (US$ Million)

Table 112. Aenova Group Recent Development

Table 113. GenScript Company Details

Table 114. GenScript Business Overview

Table 115. GenScript Biopharmaceutical CDMO Product

Table 116. GenScript Revenue in Biopharmaceutical CDMO Business (2020-2025) & (US$ Million)

Table 117. GenScript Recent Development

Table 118. ProBioGen Company Details

Table 119. ProBioGen Business Overview

Table 120. ProBioGen Biopharmaceutical CDMO Product

Table 121. ProBioGen Revenue in Biopharmaceutical CDMO Business (2020-2025) & (US$ Million)

Table 122. ProBioGen Recent Development

Table 123. Northway Biotech Company Details

Table 124. Northway Biotech Business Overview

Table 125. Northway Biotech Biopharmaceutical CDMO Product

Table 126. Northway Biotech Revenue in Biopharmaceutical CDMO Business (2020-2025) & (US$ Million)

Table 127. Northway Biotech Recent Development

Table 128. 3P Biopharmaceuticals Company Details

Table 129. 3P Biopharmaceuticals Business Overview

Table 130. 3P Biopharmaceuticals Biopharmaceutical CDMO Product

Table 131. 3P Biopharmaceuticals Revenue in Biopharmaceutical CDMO Business (2020-2025) & (US$ Million)

Table 132. 3P Biopharmaceuticals Recent Development

Table 133. Research Programs/Design for This Report

Table 134. Key Data Information from Secondary Sources

Table 135. Key Data Information from Primary Sources

Table 136. Authors List of This Report

List of Figures

Figure 1. Biopharmaceutical CDMO Picture

Figure 2. Global Biopharmaceutical CDMO Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Biopharmaceutical CDMO Market Share by Type: 2024 VS 2031

Figure 4. Cell and Gene Therapies Features

Figure 5. Antibodies Features

Figure 6. Vaccines Features

Figure 7. Other Features

Figure 8. Global Biopharmaceutical CDMO Market Size by Application (2020-2031) & (US$ Million)

Figure 9. Global Biopharmaceutical CDMO Market Share by Application: 2024 VS 2031

Figure 10. SMBs Case Studies

Figure 11. Large Companies Case Studies

Figure 12. Biopharmaceutical CDMO Report Years Considered

Figure 13. Global Biopharmaceutical CDMO Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 14. Global Biopharmaceutical CDMO Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 15. Global Biopharmaceutical CDMO Market Share by Region: 2024 VS 2031

Figure 16. Global Biopharmaceutical CDMO Market Share by Players in 2024

Figure 17. Global Top Biopharmaceutical CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biopharmaceutical CDMO as of 2024)

Figure 18. The Top 10 and 5 Players Market Share by Biopharmaceutical CDMO Revenue in 2024

Figure 19. North America Biopharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 20. North America Biopharmaceutical CDMO Market Share by Country (2020-2031)

Figure 21. United States Biopharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Canada Biopharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Biopharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Biopharmaceutical CDMO Market Share by Country (2020-2031)

Figure 25. Germany Biopharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. France Biopharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. U.K. Biopharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Italy Biopharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Russia Biopharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Nordic Countries Biopharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Biopharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Biopharmaceutical CDMO Market Share by Region (2020-2031)

Figure 33. China Biopharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Japan Biopharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. South Korea Biopharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Southeast Asia Biopharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. India Biopharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Australia Biopharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Biopharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Biopharmaceutical CDMO Market Share by Country (2020-2031)

Figure 41. Mexico Biopharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Brazil Biopharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Biopharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Biopharmaceutical CDMO Market Share by Country (2020-2031)

Figure 45. Turkey Biopharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Saudi Arabia Biopharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. UAE Biopharmaceutical CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Lonza Revenue Growth Rate in Biopharmaceutical CDMO Business (2020-2025)

Figure 49. Catalent Revenue Growth Rate in Biopharmaceutical CDMO Business (2020-2025)

Figure 50. Samsung Biologics Revenue Growth Rate in Biopharmaceutical CDMO Business (2020-2025)

Figure 51. FUJIFILM Diosynth Biotechnologies Revenue Growth Rate in Biopharmaceutical CDMO Business (2020-2025)

Figure 52. Boehringer Ingelheim Revenue Growth Rate in Biopharmaceutical CDMO Business (2020-2025)

Figure 53. WuXi AppTech Revenue Growth Rate in Biopharmaceutical CDMO Business (2020-2025)

Figure 54. Recipharm Revenue Growth Rate in Biopharmaceutical CDMO Business (2020-2025)

Figure 55. Thermo Fisher Scientific Revenue Growth Rate in Biopharmaceutical CDMO Business (2020-2025)

Figure 56. AGC Biologics Revenue Growth Rate in Biopharmaceutical CDMO Business (2020-2025)

Figure 57. Rentschler Biopharma Revenue Growth Rate in Biopharmaceutical CDMO Business (2020-2025)

Figure 58. KBI Biopharma Revenue Growth Rate in Biopharmaceutical CDMO Business (2020-2025)

Figure 59. Siegfried Revenue Growth Rate in Biopharmaceutical CDMO Business (2020-2025)

Figure 60. Aenova Group Revenue Growth Rate in Biopharmaceutical CDMO Business (2020-2025)

Figure 61. GenScript Revenue Growth Rate in Biopharmaceutical CDMO Business (2020-2025)

Figure 62. ProBioGen Revenue Growth Rate in Biopharmaceutical CDMO Business (2020-2025)

Figure 63. Northway Biotech Revenue Growth Rate in Biopharmaceutical CDMO Business (2020-2025)

Figure 64. 3P Biopharmaceuticals Revenue Growth Rate in Biopharmaceutical CDMO Business (2020-2025)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Chrysalis Oil Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-26N13078

Fri Mar 21 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Eucommia Ulmoides Extract Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-3L13782

Fri Mar 21 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global MRSA Drugs Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-26S13718

Fri Mar 21 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Ferrous Citrate Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-16S12875

Fri Mar 21 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions